At a glance
- Originator Aventis
- Developer Merck & Co
- Class Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 04 Dec 1998 No-Development-Reported for Anxiety disorders in United Kingdom (Unknown route)
- 04 Dec 1998 No-Development-Reported for Anxiety disorders in USA (Unknown route)
- 04 Dec 1998 No-Development-Reported for Parkinson's disease in United Kingdom (Unknown route)